CLINICAL PHARMACOLOGICAL APPROACH TO THE USE OF DRUGS AFFECTING THE HEMOSTASIS SYSTEM

Abstract

The homeostatic equilibrium of the coagulation cascade requires absolute precision during pharmacological manipulation. This investigation systematically evaluates the clinical outcomes of applying a strict pharmacodynamic-guided approach versus standard empirical dosing in patients receiving agents affecting the hemostasis system. Utilizing a prospective cohort design, 940 patients requiring therapeutic anticoagulation or dual antiplatelet therapy for cardiovascular and thromboembolic pathologies were monitored over 18 months. The primary objective involved quantifying the reduction in hemorrhagic and ischemic complications when drug selection and titration were strictly governed by individualized pharmacokinetic parameters and specific point-of-care coagulation assays. Patients subjected to targeted monitoring (n = 470) exhibited a sharp decline in major bleeding events, dropping to 1.8% compared to 5.4% in the empirically treated cohort (Relative Risk = 0.33, 95% CI: 0.19-0.58). Simultaneously, the incidence of recurrent thromboembolism remained structurally contained at 1.2% in the monitored group versus 3.1% in standard care. Transitioning from fixed-dose direct oral anticoagulants to anti-Xa-guided therapy in patients with borderline renal function specifically neutralized drug accumulation toxicity. The empirical data mathematically validate that utilizing advanced clinical pharmacological algorithms completely restructures the safety profile of hemostatic modulators. Substituting generalized prescribing patterns with precision therapeutic drug monitoring is mandatory to safely navigate the extremely narrow therapeutic indices inherent to these potent agents.